Role of fibroblast growth factor-23 as an early marker of metabolic bone disease of prematurity.

ABSTRACT:

Purpose

Metabolic bone disease of prematurity (MBDP) remains a significant cause of morbidity in extremely premature newborns. In high-risk patients, suspected diagnosis and subsequent treatment modifications, with limitations in terms of sensitivity and specificity, rely on low phosphorus levels and/or high levels of alkaline phosphatase (ALP). We investigated the potential of fibroblast growth factor-23 (FGF23) as an early marker for MBDP when measured at 3-4 weeks of life in at-risk patients.

Methods

A single-center prospective observational non-interventional study including preterm newborns of both sexes, with a gestational age of less than 32 weeks and/or a birth weight of less than 1500 g. In the standard biochemical screening for MBDP performed between 3 and 4 weeks

SUBMITTER: Llorente-Pelayo S 

PROVIDER: S-EPMC11218264 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature